Literature DB >> 31181959

More CREDENCE for SGLT2 Inhibition.

Subodh Verma1, Deepak L Bhatt2.   

Abstract

Entities:  

Keywords:  cardiovascular diseases; diabetes mellitus; diabetic nephropathies; kidney failure, chronic

Mesh：

Substances：

Year:  2019        PMID： 31181959     DOI： 10.1161/CIRCULATIONAHA.119.041181

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  3 in total

1.  SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.

Authors:  Rhanderson Cardoso; Fabrissio P Graffunder; Caique M P Ternes; Amanda Fernandes; Ana V Rocha; Gilson Fernandes; Deepak L Bhatt
Journal:  EClinicalMedicine       Date:  2021-06-05

2.  Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study.

Authors:  Yen-Chieh Lee; Yaa-Hui Dong; Wei-Shun Yang; Li-Chiu Wu; Jou-Wei Lin; Chia-Hsuin Chang
Journal:  Front Pharmacol       Date:  2022-09-13       Impact factor: 5.988

Review 3.  Lipid mediators of insulin signaling in diabetic kidney disease.

Authors:  Alla Mitrofanova; Marie Anne Sosa; Alessia Fornoni
Journal:  Am J Physiol Renal Physiol       Date:  2019-09-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.